Regeneron Pharmaceuticals Inc (REGN)

Price$635.45

Value ScoreC

Growth ScoreC

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-26.48%

Price vs S&P 500 (4W)-11.10%

VGM Score52.75

Market Capitalization$66.62B

P/E Ratio (Annual)14.79x

Indicated Dividend Yield (Annual)0.60%

All Metrics

P/CF (Annual)13.38x

Book Value / Share (Quarterly)$299.27

P/TBV (Annual)2.70x

Indicated Dividend (Annual)$3.76

Revenue Growth (3Y)5.62%

Cash Flow / Share (Quarterly)$36.10

Payout Ratio (TTM)8.46%

Price vs S&P 500 (YTD)-25.83%

Gross Margin (TTM)85.70%

Net Profit Margin (TTM)29.65%

EPS (TTM)$41.03

10-Day Avg Trading Volume1.23M

EPS Excl Extra (TTM)$41.03

Revenue Growth (5Y)11.04%

EPS (Annual)$41.48

Dividend / Share (Annual)$3.44

ROI (Annual)13.26%

Gross Margin (Annual)86.56%

Net Profit Margin (5Y Avg)35.70%

Cash / Share (Quarterly)$83.37

P/E Basic Excl Extra (TTM)15.06x

Revenue Growth QoQ (YoY)19.04%

EPS Growth (5Y)6.33%

P/E Normalized (Annual)14.79x

ROA (Last FY)11.11%

Revenue Growth TTM (YoY)5.92%

EBITD / Share (TTM)$38.67

ROE (5Y Avg)21.37%

Operating Margin (TTM)24.32%

Cash Flow / Share (Annual)$35.62

P/B Ratio2.12x

P/B Ratio (Quarterly)2.60x

Net Income / Employee (Annual)$292,300

EV / Revenue (TTM)4.45x

Net Interest Coverage (TTM)49.98x

ROA (TTM)11.07%

EPS Growth QoQ (YoY)-7.16%

EV / EBITDA (TTM)15.92x

EPS Incl Extra (Annual)$41.48

Current Ratio (Annual)4.13x

Quick Ratio (Quarterly)2.99x

3-Month Avg Trading Volume0.82M

52-Week Price Return31.54%

EV / Free Cash Flow (Annual)17.63x

P/E Incl Extra (TTM)15.06x

Revenue / Employee (TTM)$968,200

Tangible BV / Share (Quarterly)$287.02

P/S Ratio (Annual)4.64x

Asset Turnover (Annual)0.35x

52-Week High$821.11

Operating Margin (5Y Avg)35.70%

EPS Excl Extra (Annual)$41.48

CapEx CAGR (5Y)14.58%

Tangible BV CAGR (5Y)28.76%

26-Week Price Return-18.55%

Quick Ratio (Annual)3.45x

13-Week Price Return-16.93%

Total Debt / Equity (Annual)0.09x

Current Ratio (Quarterly)3.56x

Enterprise Value$66.36B

Revenue / Share Growth (5Y)12.34%

Asset Turnover (TTM)0.37x

Book Value / Share Growth (5Y)23.46%

Revenue / Employee (Annual)$930,800

Inventory Turnover (Annual)0.69x

Pretax Margin (Annual)36.47%

Cash / Share (Annual)$81.41

3-Month Return Std Dev33.39%

Gross Margin (5Y Avg)87.22%

Net Income / Employee (TTM)$287,000

EBITDA CAGR (5Y)1.57%

EBITDA Interim CAGR (5Y)-8.28%

ROE (Last FY)14.41%

Net Interest Coverage (Annual)19.07x

EPS Basic Excl Extra (Annual)$41.48

P/FCF (TTM)17.57x

Receivables Turnover (TTM)2.64x

EV / Free Cash Flow (TTM)17.51x

Total Debt / Equity (Quarterly)0.09x

EPS Incl Extra (TTM)$41.03

Receivables Turnover (Annual)2.40x

ROI (TTM)13.16%

P/S Ratio (TTM)4.47x

Pretax Margin (5Y Avg)40.02%

Revenue / Share (Annual)$132.07

Tangible BV / Share (Annual)$283.82

Forward P/E12.38x

Free OCF CAGR (5Y)13.45%

Price vs S&P 500 (52W)7.18%

P/E Ratio (TTM)15.06x

EPS Growth TTM (YoY)4.40%

Year-to-Date Return-17.67%

5-Day Price Return5.79%

EPS Normalized (Annual)$41.48

ROA (5Y Avg)16.27%

Net Profit Margin (Annual)31.41%

Month-to-Date Return3.36%

Cash Flow / Share (TTM)$38.82

EBITD / Share (Annual)$37.95

EPS Growth (3Y)2.76%

Operating Margin (Annual)24.95%

LT Debt / Equity (Annual)0.06x

P/CF (TTM)13.29x

ROI (5Y Avg)19.10%

P/E Excl Extra (TTM)15.06x

LT Debt / Equity (Quarterly)0.06x

EPS Basic Excl Extra (TTM)$41.03

P/TBV (Quarterly)2.71x

Payout Ratio (Annual)8.22%

P/B Ratio (Annual)2.60x

Dividend / Share (TTM)$3.51

Inventory Turnover (TTM)0.77x

Pretax Margin (TTM)34.56%

Book Value / Share (Annual)$295.71

Price vs S&P 500 (13W)-25.18%

Net Margin Growth (5Y)-5.35%

Dividend Yield (TTM)0.56%

Beta0.23x

P/FCF (Annual)17.69x

Revenue / Share (TTM)$138.53

ROE (TTM)14.32%

52-Week Low$476.49

vGradeC

gGradeC

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 269.47est. 9.12

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.06

4.08

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
REGNRegeneron Pharmaceuticals Inc	C	C	C	$635.45
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Regeneron Pharmaceuticals discovers and commercializes biopharmaceutical products across ophthalmology, immunology, cardiovascular disease, oncology, and rheumatology, with marketed drugs including Eylea HD, Dupixent, Praluent, Libtayo, and Kevzara. The company develops monoclonal and bispecific antibodies independently and through collaborations, including a partnership with Sanofi. Regeneron is advancing next-generation therapies through early-stage partnerships in RNAi and CRISPR-based gene editing.